SMS Pharma close to sale of Indian oncology facility
This article was originally published in Scrip
Executive Summary
The Indian active pharmaceuticals ingredients company, SMS Pharmaceuticals, looks set to divest its oncology manufacturing facility near Visakhapatnam, amid speculation that Mylan could be among the potential buyers.